Apremilast 30 mg Twice Daily (BID) Combined With Dupilumab

Summary

Open label phase 2 investigational study of efficacy and safety of apremilast 30 mg twice a day (BID) in chronic atopic dermatitis when added to the FDA approved treatment dupilumab for atopic dermatitis that is not providing adequate clinical responses.

Timeline

Start

2020-08-01

Primary completion

2022-06-23

Completion

2022-08-18

Drugs

Indications